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We read with interest the article by
Kopylov et al,1 particularly with respect to
the increased risk of nonmelanoma skin
cancer (NMSC) seen in patients with
inflammatory bowel disease (IBD) on thi-
opurines. Previous studies have also
shown that patients with IBD with previ-
ous and ongoing exposure to thiopurines
are at increased risk.2,3 Importantly, unlike
lymphoma risk,4 the risk of NMSC
persists even after discontinuation of
thiopurines, suggesting a mechanism of
nonreversible DNA damage.
O’Donovan et al5 previously
observed that azathioprine users experi-
enced a reduction in the minimal erythema
dose (MED) of UV-A, the lowest amount
of radiation required to produce percepti-
ble erythema 24 hours after skin irradia-
tion. This finding suggests that skin cancer
risk may be due to mutagenic DNA dam-
age from UV-A exposure. Additional
work is needed to evaluate the effects of
thiopurine and other immune suppressant
treatments on both UV-A and UV-B
(wavelengths most associated with sun-
burn) photosensitivity. We piloted MED
testing before and after initiation of thio-
purines or anti–tumor necrosis factor
(TNF) in patients with IBD. Feasibility,
obstacles, and estimations of effect size
were assessed. We compared mean MED
(joules per square centimeter) before and
after and calculated 95% confidence inter-
vals for the difference.
We included 3 patients initiating
thiopurines and 2 initiating anti-TNF.
For UV-A testing, thiopurines reduced
MED (increased photosensitivity), from
mean of 17.3 to 14.6 J/cm2 (difference,
22.6 J/cm2, 95% confidence interval,
28.3 to 3.0). Anti-TNF agents showed
similar pre-MED and post-MED (mean,
15.9 and 14.0 J/cm2, respectively, differ-
ence,21.9 J/cm2, 95% confidence interval,
229.2 to 25.5). For UV-B testing, neither
class was associated with MED reduction
(mean: 254 J/cm2 before and 294 J/cm2
after for thiopurines and 224 J/cm2 before
and after for anti-TNF) (Fig. 1).
MED testing is feasible, although time
intensive and technically difficult. Neither
thiopurines nor anti-TNF agents increased
UV-B photosensitivity. We hypothesize that
UV-A photosensitivity may be a factor in the
increased NMSC risk in patients with IBD
on immunosuppression; larger sample sizes
are needed for confirmation.
Kopylov et al recommended skin
cancer screening in patients with IBD.
Although primary prevention of NMSC
in patients with IBD through broad-
spectrum sunscreen use is warranted,
FIGURE 1. Minimal erythema dose testing for Ultraviolet-A and Ultraviolet-B light in 5 patients
with IBD newly initiating therapy.
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we must consider the requirements for
implementing a screening test as outlined
by the United States Preventive Services
Task Force, including the requirement for
evidence that the early detection reduces
mortality and morbidity—data we do not
yet have in IBD. We agree that skin
cancer risk awareness should be dis-
cussed in patients with IBD on immuno-
suppression and preventive efforts are
warranted.
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